Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Nystatin
Accession Number
DB00646  (APRD01146)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Nystatin is a polyene antifungal drug that has broad-spectrum fungicidal and fungistatic activity against a number of yeasts and fungi, most notably Candida species.8 It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of Streptomyces noursei,13 and is closely related to amphotericin B, differing only slightly in structure.2 Nystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate for systemic use.2 As it undergoes very little absorption following oral or topical administration, nystatin's efficacy is limited to the treatment/prevention of cutaneous, mucocutaneous, and gastrointestinal fungal infections.8,9

Structure
Thumb
Synonyms
  • Nistatina
  • NYS
  • Nystatin
  • Nystatine
  • Nystatinum
Product Ingredients
IngredientUNIICASInChI Key
Nystatin dihydrateNot AvailableNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MestatinCreamVaginalMedic Laboratory LtÉe1980-12-311996-09-09Canada
Mycostatin Oral Suspension 100000iuLiquidOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1972-12-312003-07-28Canada
Mycostatin Oral Tab 500000iuTabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada
Mycostatin Vaginal Crm 25000unitCreamVaginalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1973-12-312005-08-01Canada
Nadostine Sus 100000iu/mlSuspensionOralLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada
Nadostine Tab 100000unitTabletVaginalLab Nadeau LtÉe, Division Of Technilab Inc.1973-12-312004-08-03Canada
Nadostine Tab 500000unitTabletOralLab Nadeau LtÉe, Division Of Technilab Inc.1973-12-311999-09-28Canada
Nilstat 25000units/gCreamVaginalTechnilab Pharma Inc.1974-12-312004-08-03Canada
Nilstat Oral Dps 100000iu/mlSolution / dropsOralLederle Cyanamid Canada Inc.1970-12-311997-01-29Canada
Nilstat Orl Tab 500000unitTabletOralLederle Cyanamid Canada Inc.1970-12-311997-01-29Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-nystatin SuspensionSuspensionOralDominion Pharmacal1998-08-05Not applicableCanada
Ftp-nystatinSolution / dropsOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Jamp-nystatin Oral Suspension USPSuspensionOralJamp Pharma Corporation2015-01-09Not applicableCanada
MycostatinPowder100000 [USP'U]/1gTopicalE.R. Squibb & Sons, L.L.C.2009-06-012010-03-31Us
MycostatinCream100000 [USP'U]/1gTopicalE.R. Squibb & Sons, L.L.C.2007-01-012007-06-30Us
NyamycPowder100000 [USP'U]/1gTopicalUpsher-Smith Laboratories, LLC2005-05-03Not applicableUs
NyataKit100000 U/1gCrown Laboratories2015-12-172016-10-03Us
Nyata Nystatin PowderKit100000 U/1gTopicalCrown Laboratories2016-12-082017-01-02Us
NystatinCream100000 [USP'U]/1gTopicalNucare Pharmaceuticals,inc.1993-01-28Not applicableUs
NystatinCream100000 [USP'U]/1gTopicalA-S Medication Solutions2006-09-21Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Candistatin Topical Powder - 100000 Unit/gPowderTopicalBristol Myers Squibb1996-12-312008-04-25Canada
Mycostatin Crm 100000unit/gmCreamTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1970-12-312006-09-06Canada
Mycostatin Ont 100000iu/gmOintmentTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada
Mycostatin Topical Pwr 100,000units/gmPowderTopicalConvatec, Division Of Bristol Myers Squibb Canada Co.1994-12-312008-11-12Canada
Nadostine Crm 100000iu/gmCreamTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada
Nadostine Ont 100000iu/gmOintmentTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada
Nilstat Top Crm 100000unit/gmCreamTopicalLederle Cyanamid Canada Inc.1979-12-311997-01-29Canada
Nilstat Top Ont 100000unit/gmOintmentTopicalLederle Cyanamid Canada Inc.1979-12-311997-01-29Canada
Nyaderm Crm 100000unit/gmCreamTopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Nyaderm Ont 100000unit/gmOintmentTopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FlagystatinNystatin (100000 unit) + Metronidazole (500 mg)CreamVaginalSanofi Aventis1976-12-312017-08-24Canada
FlagystatinNystatin (100000 unit) + Metronidazole (500 mg)SuppositoryVaginalSanofi Aventis1979-12-31Not applicableCanada
FlagystatinNystatin (100000 unit) + Metronidazole (500 mg)SuppositoryVaginalAventis Pharma Ltd.1972-12-312004-07-30Canada
Kenacomb CreamNystatin (100000 unit) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Triamcinolone acetonide (1 mg)CreamTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1965-12-312004-08-05Canada
Kenacomb Mild CreamNystatin (100000 unit) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Triamcinolone acetonide (.25 mg)CreamTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1968-12-312004-08-05Canada
Kenacomb Mild OintmentNystatin (100000 unit) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Triamcinolone acetonide (.25 mg)OintmentTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1968-12-312004-08-05Canada
Kenacomb OintmentNystatin (100000 unit) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Triamcinolone acetonide (1 mg)OintmentTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1996-07-312004-08-05Canada
Kenacomb OntNystatin (100000 unit) + Gramicidin D (.25 mg) + Neomycin (2.5 mg) + Triamcinolone acetonide (1 mg)OintmentTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1965-12-311997-08-14Canada
Lidecomb CreamNystatin (100000 unit) + Fluocinonide (0.5 mg) + Gramicidin D (0.25 mg) + Neomycin sulfate (5 mg)CreamTopicalMedicis Pharmaceutical Corporation1980-12-311998-09-25Canada
Mecomb Crm 0.1%Nystatin (100000 unit) + Gramicidin D (.25 mg) + Neomycin (2.5 mg) + Triamcinolone acetonide (1 mg)CreamTopicalMedic Laboratory LtÉe1979-12-312003-07-17Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FIRST BXN MouthwashNystatin (6.75 mg/1mL) + Diphenhydramine hydrochloride (0.84 mg/1mL) + Lidocaine hydrochloride (6.75 mg/1mL)KitOralCutisPharma, Inc2009-09-08Not applicableUs
FIRST Dukes Mouthwash CompoundingNystatin (0.6 g/0.6g) + Diphenhydramine hydrochloride (0.525 g/0.525g) + Hydrocortisone (0.06 g/0.06g)KitOralCutisPharma, Inc.2010-12-15Not applicableUs
FIRST Marys Mouthwash CompoundingNystatin (1.2 g/1.2g) + Diphenhydramine hydrochloride (0.45 g/0.45g) + Hydrocortisone (0.06 g/0.06g) + Tetracycline hydrochloride (1.5 g/1.5g)KitOralCutisPharma, Inc.2010-12-15Not applicableUs
International/Other Brands
Adiclair (Ardeypharm) / Afunginal (Euro Generics) / Biofanal (Pfleger) / Candacide (Be-Tabs Pharmaceuticals) / Candermil (LKM) / Candex (Square) / Candidias (Fabra) / Candistat (Ambalal Sarabhai Enterprises) / Candistin (Pharos) / Canstat (Aspen Pharmacare) / Cazetin (Ifars) / Diaper NZ (Cheminter) / Dipni (Omega) / Enystin (Kalbe) / Fukangning (Deyer) / Fungatin (Ferron) / Fungicidin Leciva (Zentiva) / Fungistin (Beximco) / Fungostatin (Nobel) / Funistatin (Nobel) / Gynostatin (Iqfarma) / Kandistatin (Metiska) / Kenalon (Ta Fong) / Lederlind (Riemser) / Ledernyst (Riemser) / Lystin (Biolab) / Nilstat (Glenmark) / Nyaderm (Taro) / Nystan (Bristol Myers Squibb)
Categories
UNII
BDF1O1C72E
CAS number
1400-61-9
Weight
Average: 926.107
Monoisotopic: 925.503499959
Chemical Formula
C47H75NO17
InChI Key
VQOXZBDYSJBXMA-RKEBNKJGSA-N
InChI
InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-36(53)35(52)20-19-31(49)21-32(50)22-33(51)23-39(55)62-29(3)28(2)42(27)56/h5-6,8,10-18,27-38,40-44,46,49-54,56-58,61H,7,9,19-26,48H2,1-4H3,(H,59,60)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31?,32?,33?,34?,35?,36?,37?,38?,40?,41-,42+,43+,44-,46+,47+/m0/s1
IUPAC Name
(1S,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E)-33-{[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid
SMILES
C[C@H]1O[C@H](OC2CC3O[C@@](O)(CC(O)C3C(O)=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O

Pharmacology

Indication

Nystatin is available in oral formulations for the treatment and/or prevention of oral candidiasis (a.k.a. thrush), intestinal candidiasis, and anal candidiasis.8,9 It is indicated topically for the treatment of vulvovaginal candidiasis and other cutaneous candida infections.9 A combination product containing nystatin alongside neomycin, gramicidin D, and triamcinolone (Viaderm K.C.®) is indicated in the treatment of corticosteroid-responsive dermatoses caused by bacterial or candidal infections and for pruritus ani/vulvae.10 It is also available in combination with metronidazole for the treatment of mixed infections due to Trichomonas vaginalis and Candida albicans.13

Nystatin is also sometimes used off-label for the prevention of invasive candidiasis in low birth weight neonates,4 though it is generally reserved as a second-line option after fluconazole.

Associated Conditions
Pharmacodynamics

Nystatin is an antifungal that is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. It exerts its antifungal effects via disruption of the fungal cell membrane. Resistance to nystatin is minimal in Candida albicans, but tends to develop in other species of Candida.8 Nystatin carries no significant activity against bacteria, protozoa, or viruses. It carries significant systemic toxicity and is currently unavailable in a formula appropriate for systemic use - its efficacy is currently restricted, therefore, to topical, oral, and gastrointestinal infections.2

Mechanism of action

Nystatin is a channel-forming ionophore, meaning it exerts its therapeutic effect via formation of a membrane-spanning pore in the fungal plasma membrane.5 The formation of this pore results in a change in membrane permeability that allows for leakage of intracellular contents and the subsequent disruption of electrochemical gradients necessary for proper cell function.8,2 Selectivity for fungal cells over mammalian cells is due to nystatin’s greater binding affinity for ergosterol, a key sterol found in fungal cell walls, as opposed to its mammalian counterpart, cholesterol.6

TargetActionsOrganism
AErgosterol
binder
Candida albicans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Systemic absorption of nystatin is minimal following oral administration,8 and no detectable plasma concentrations are attained following topical or vaginal administration.12

Volume of distribution

Nystatin is not absorbed into the systemic circulation8 and thus does not undergo distribution.

Protein binding

Nystatin is not absorbed into the systemic circulation8 and is therefore not subject to plasma protein binding.

Metabolism

Because nystatin undergoes little-to-no systemic absorption it is not metabolized to any appreciable extent.8

Route of elimination

The majority of orally administered nystatin is eliminated unchanged in the feces.8

Half life
Not Available
Clearance
Not Available
Toxicity

The oral LD50 in rats is 10 g/kg.11 There have been no reports of serious toxic effects following overdosage of nystatin - doses in excess of five million units daily have resulted in nausea and gastrointestinal upset with no other associated effects.8

Affected organisms
  • Fungi
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbrisentanThe excretion of Ambrisentan can be decreased when combined with Nystatin.
AsunaprevirThe excretion of Asunaprevir can be decreased when combined with Nystatin.
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Nystatin.
AtrasentanThe excretion of Atrasentan can be decreased when combined with Nystatin.
AxitinibThe excretion of Axitinib can be decreased when combined with Nystatin.
BenzylpenicillinThe excretion of Benzylpenicillin can be decreased when combined with Nystatin.
BosentanThe excretion of Bosentan can be decreased when combined with Nystatin.
CaspofunginThe excretion of Caspofungin can be decreased when combined with Nystatin.
CerivastatinThe excretion of Cerivastatin can be decreased when combined with Nystatin.
CholecystokininThe excretion of Cholecystokinin can be decreased when combined with Nystatin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take without regard to meals.

References

General References
  1. Akaike N, Harata N: Nystatin perforated patch recording and its applications to analyses of intracellular mechanisms. Jpn J Physiol. 1994;44(5):433-73. [PubMed:7534361]
  2. Dos Santos AG, Marques JT, Carreira AC, Castro IR, Viana AS, Mingeot-Leclercq MP, de Almeida RFM, Silva LC: The molecular mechanism of Nystatin action is dependent on the membrane biophysical properties and lipid composition. Phys Chem Chem Phys. 2017 Nov 15;19(44):30078-30088. doi: 10.1039/c7cp05353c. [PubMed:29098221]
  3. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]
  4. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16. [PubMed:26679628]
  5. Yamasaki M, Tamura N, Nakamura K, Sasaki N, Murakami M, Rajapakshage W, Kumara B, Tamura Y, Lim SY, Ohta H, Takiguchi M: Effects and mechanisms of action of polyene macrolide antibiotic nystatin on Babesia gibsoni in vitro. J Parasitol. 2011 Dec;97(6):1190-2. doi: 10.1645/GE-2799.1. Epub 2011 Jul 14. [PubMed:21756054]
  6. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [PubMed:16500971]
  7. Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S: A Drug-drug Interaction Between Cyclosporine and Nystatin. Clin Ther. 2018 Apr;40(4):660-662. doi: 10.1016/j.clinthera.2018.02.008. Epub 2018 Mar 16. [PubMed:29551534]
  8. FDA Approved Drug Products: Nystatin oral suspension [Link]
  9. DPD Approved Drugs: Nystatin [Link]
  10. DPD Approved Drugs: Viaderm K.C.® [Link]
  11. ThermoFisher Scientific: Nystatin MSDS [Link]
  12. MedSafe NZ: Nystatin [Link]
  13. DPD Approved Drugs: Flagystatin® vaginal ovules [Link]
External Links
Human Metabolome Database
HMDB0014784
KEGG Drug
D00202
KEGG Compound
C06572
PubChem Compound
11953884
PubChem Substance
46504780
ChemSpider
10468627
ChEBI
473992
ChEMBL
CHEMBL229383
Therapeutic Targets Database
DAP000879
PharmGKB
PA450666
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nystatin
ATC Codes
D01AA01 — NystatinG01AA01 — NystatinA07AA02 — NystatinG01AA51 — Nystatin, combinations
AHFS Codes
  • 84:04.08.28 — Polyenes
  • 08:14.28 — Polyenes
FDA label
Download (776 KB)
MSDS
Download (72.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOral Lichen Planus1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
2CompletedPreventionOral Mucositis1
2CompletedTreatmentStomatitis, Denture1
2Not Yet RecruitingPreventionAllogeneic Hematopoietic Stem Cell Transplantation Recipient / Graft-versus-host Disease Prevention1
2Unknown StatusTreatmentAnastomotic Leakage1
2, 3Unknown StatusPreventionBacteremia / Bacteremia Associated With Intravascular Line / Ventilator-associated Bacterial Pneumonia1
2, 3WithdrawnTreatmentMinor burns1
3Active Not RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3CompletedSupportive CareChronic Myeloproliferative Disorders / Infection / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
3CompletedTreatmentGastrointestinal Diseases / Oral Candidiasis / Stomatitis1
3CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection1
3CompletedTreatmentOral Candidiasis1
3RecruitingPreventionCritical Illness / Sepsis / Shock, Septic / Ventilator-associated Bacterial Pneumonia1
3Unknown StatusTreatmentBacterial Vaginosis (BV) / Fungal Vaginal Infections1
4CompletedHealth Services ResearchChronic Renal Failure (CRF)1
4CompletedPreventionCritical Illness / Fungal Prophylaxis / General Surgery / Prophylaxis of Candida Infections1
4CompletedPreventionSystemic Fungal Infections1
4CompletedPreventionVery Low Birth Weight Infants1
4CompletedTreatmentPhotochemotherapy Reaction1
4CompletedTreatmentVaginal Inflammation1
4Enrolling by InvitationPreventionOral Mucositis1
4TerminatedTreatmentMinor burns1
4Unknown StatusPreventionAnticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight Infants1
Not AvailableCompletedPreventionOral Lichen Planus / Prophylaxis of Candida Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Oral Candidiasis3
Not AvailableCompletedTreatmentPeriodontal Diseases1
Not AvailableUnknown StatusNot AvailableStomatitis, Denture1

Pharmacoeconomics

Manufacturers
  • Bayer pharmaceuticals corp
  • Bristol myers squibb co
  • Alpharma us pharmaceuticals division
  • Lederle laboratories div american cyanamid co
  • Actavis mid atlantic llc
  • Altana inc
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Westwood squibb pharmaceuticals inc
  • Bristol myers squibb
  • Barlan pharmacal co inc
  • Dava pharmaceuticals inc
  • Paddock laboratories inc
  • Coastal pharmaceuticals inc
  • Kv pharmaceutical co
  • Par pharmaceutical inc
  • Upsher smith laboratories inc
  • X gen pharmaceuticals inc
  • Warner chilcott co llc
  • Apothecon inc div bristol myers squibb
  • Glenmark generics inc usa
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Morton grove pharmaceuticals inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Roxane laboratories inc
  • Vintage pharmaceuticals inc
  • Vistapharm inc
  • Wockhardt eu operations (swiss) ag
  • Savage laboratories inc div altana inc
  • Mutual pharmaceutical co inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
  • Holland rantos co inc
  • Odyssey pharmaceuticals inc
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Apothecon
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bausch & Lomb Inc.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Contract Pharm
  • Cutis Pharma Inc.
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • E. Fougera and Co.
  • E.R. Squibb and Sons LLC
  • Gallipot
  • Glenmark Generics Ltd.
  • Major Pharmaceuticals
  • Medisca Inc.
  • Metrics Inc.
  • Midlothian Labs
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Novopharm Ltd.
  • Nycomed Inc.
  • Odyssey Pharmaceuticals Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • PEDiNOL
  • Perrigo Co.
  • Pharmaceutical Association
  • Pharmaceutics International Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Precision Dose Inc.
  • Preferred Pharmaceuticals Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Sandoz
  • Savage Labs
  • Stat Scripts LLC
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • USL Pharma Inc.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Wockhardt Ltd.
  • Xactdose Inc.
  • X-Gen Pharmaceuticals
Dosage forms
FormRouteStrength
KitOral
CreamVaginal
SuppositoryVaginal
Solution / dropsOral
PowderTopical100000 [USP'U]/1g
LiquidOral
PowderTopical
SuspensionOral
TabletVaginal
TabletOral
CreamVaginal
Kit100000 U/1g
KitTopical100000 U/1g
CreamTopical100000 U/1g
CreamTopical100000 mg/1g
CreamTopical100000 [USP'U]/1g
InsertVaginal100000 [USP'U]/1
OintmentTopical100000 U/1g
OintmentTopical100000 [USP'U]/1g
OintmentTopical100000 1/1g
PowderTopical100000 1/1g
PowderTopical100000
Powder, for suspensionOral5000
SuspensionOral100000 [USP'U]/15mL
SuspensionOral100000 [iU]/1mL
SuspensionOral100000 [USP'U]/1mL
SuspensionOral100000
SuspensionOral500000 [USP'U]/5mL
Tablet, coatedOral500000 [USP'U]/1
Tablet, film coatedOral500000 [USP'U]/1
CreamTopical
OintmentTopical
PowderTopical100000 U/1g
KitTopical100000 [USP'U]/1g
CreamTopical
OintmentTopical
Prices
Unit descriptionCostUnit
Nystatin 10 billion unit powder3014.1USD each
Nystatin 5 billion unit powder2096.1USD each
Nystatin 2 billion unit powder1116.9USD each
Nystatin 1 billion unit powder452.08USD each
Nystat-rx 5 billion unit powder447.0USD each
Nystatin 500 million unit powder130.75USD each
Pedi-Dri 100000 unit/gm Powder 56.7 gm Bottle105.87USD bottle
Nystatin 150mu Bottle94.5USD bottle
Nystatin 150 million unit powder42.25USD each
Nystatin 150000000 unit powder42.0USD each
Nystatin Nystatin Powder 50 Million unit Bottle39.99USD bottle
Mycostatin 100000 unit/gm Powder 15 gm Bottle36.99USD bottle
Nystop 100000 unit/gm Powder 15 gm Bottle29.99USD bottle
Nystatin 50 million unit powder19.75USD each
Nystatin 100000 unit/gm Ointment 15 gm Tube12.99USD tube
Nystatin 100000 unit/gm Cream 15 gm Tube6.5USD tube
Nystatin 100000 unit tablet5.29USD tablet
Nystatin vaginal tablet5.0USD tablet
Pedi-dri topical powder1.82USD g
Nystop 100000 unit/gm powder1.6USD g
Nystatin 500000 unit tablet0.71USD tablet
Nystatin 500000 unit oral tablet0.68USD tablet
Mycostatin 500000 unit orl tablet0.48USD tablet
Nystatin 100000 unit/ml Suspension0.25USD ml
Ratio-Nystatin 500000 unit Tablet0.25USD tablet
Nystatin 100000 unit/gm cream0.1USD g
Pms-Nystatin 100000 unit/ml Suspension0.05USD ml
Ratio-Nystatin 100000 unit/ml Suspension0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)160 °C (decomposes)MSDS
water solubility360 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.086 mg/mLALOGPS
logP-3.1ALOGPS
logP-1.9ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.61ChemAxon
pKa (Strongest Basic)9.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count12ChemAxon
Polar Surface Area319.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity243.55 m3·mol-1ChemAxon
Polarizability99.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8641
Blood Brain Barrier-0.9581
Caco-2 permeable-0.741
P-glycoprotein substrateSubstrate0.5182
P-glycoprotein inhibitor INon-inhibitor0.814
P-glycoprotein inhibitor IINon-inhibitor0.6721
Renal organic cation transporterNon-inhibitor0.96
CYP450 2C9 substrateNon-substrate0.8313
CYP450 2D6 substrateNon-substrate0.867
CYP450 3A4 substrateNon-substrate0.5273
CYP450 1A2 substrateNon-inhibitor0.916
CYP450 2C9 inhibitorNon-inhibitor0.9374
CYP450 2D6 inhibitorNon-inhibitor0.9354
CYP450 2C19 inhibitorNon-inhibitor0.9243
CYP450 3A4 inhibitorNon-inhibitor0.931
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.987
Ames testNon AMES toxic0.8992
CarcinogenicityNon-carcinogens0.9731
BiodegradationNot ready biodegradable0.8601
Rat acute toxicity2.1245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.8971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Small molecule
Organism
Candida albicans
Pharmacological action
Yes
Actions
Binder
References
  1. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [PubMed:16500971]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]

Drug created on June 13, 2005 07:24 / Updated on January 18, 2020 13:26